RHOJ controls EMT-associated resistance to chemotherapy.

ABSTRACT: The resistance of cancer cells to therapy is responsible for the death of most patients with cancer¹. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to therapy in different cancer cells^2,3. However, the mechanisms by which EMT mediates resistance to therapy remain poorly understood. Here, using a mouse model of skin squamous cell carcinoma undergoing spontaneous EMT during tumorigenesis, we found that EMT tumour cells are highly resistant to a wide range of anti-cancer therapies both in vivo and in vitro. Using gain and loss of function studies in vitro and in vivo, we found that RHOJ-a small GTPase that is preferentially expressed in EMT cancer cells-controls resistance to therapy. Using genome-wide transcriptomic and proteomic profili

SUBMITTER: Debaugnies M 

PROVIDER: S-EPMC10076223 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature